Avacta Group PLC Result of General Meeting (7074U)
July 31 2015 - 5:42AM
UK Regulatory
TIDMAVCT
RNS Number : 7074U
Avacta Group PLC
31 July 2015
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT
FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN
OR THE REPUBLIC OF SOUTH AFRICA IN WHOLE OR IN PART, OR ANY
JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION IS
PROHIBITED.
31 July 2015
Avacta Group plc
("Avacta" or the "Group")
Result of General Meeting
Avacta Group plc (LSE: AVCT), the global provider of proprietary
diagnostic tools, consumables and reagents for life sciences, is
pleased to announce that the Resolutions put to shareholders at
today's General Meeting in connection with the Placing announced by
the Company on 15 July 2015, were duly passed.
Following the passing of the Resolutions at the General Meeting,
a total of 1,760,000,000 new Ordinary Share s, have been allotted
to existing and new investors, conditional upon the admission of
such Ordinary Shares to trading on AIM.
It is expected that settlement will occur, admission to trading
on AIM will become effective and dealings will commence in respect
of the 1,760,000,000 new Ordinary Shares, at 8.00am on 3 August
2015.
Upon admission, the Placing Shares will be issued, credited as
fully paid and will rank pari passu in all respects with the
existing Ordinary Shares of the Company.
Following admission of the 1,760,000,000 new Ordinary Shares to
trading on AIM, the total number of Ordinary Shares with voting
rights in issue will be 6,739,649,550 and this figure may be used
by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the Company under the
Financial Conduct Authority's Disclosure and Transparency
Rules.
Capitalised terms in this announcement have the same meaning as
in the circular sent to Shareholders in connection with the Placing
on 15 July 2015.
For further information:
Avacta Group plc Tel: +44 (0) 844 414
Alastair Smith, Chief Executive Officer 0452
Tim Sykes, Chief Financial Officer www.avacta.com
Numis Securities Limited Tel: +44 (0) 207 260
Michael Meade / Freddie Barnfield - Nominated 1000
Adviser www.numiscorp.com
James Black - Corporate Broking
WG Partners LLP - Joint Broker Tel: +44 (0) 203 705
David Wilson 9330
Claes Spång www.wgpartners.co.uk
Media Enquiries Tel: +44 (0) 20 3727
FTI Consulting 1000
Simon Conway/Natalie Garland-Collins avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta Group plc is a global provider of innovative
technologies, consumables and reagents for the life science
markets, from drug discovery to diagnostics. Avacta's principal
focus is on its proprietary Affimer(R) technology which is a novel
engineered alternative to antibodies that has wide application in
Life Sciences for diagnostics, therapeutics and general research
and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. Affimers have been designed to address many of
these negative performance issues, principally: the time taken to
generate new antibodies, the reliance on an animal's immune
response, poor specificity in many cases, and batch to batch
variability. Affimers are based on a small protein that can be
quickly generated to bind with high specificity and affinity to a
wide range of protein targets.
Avacta is commercialising the Affimer reagents through custom
Affimer services to provide bespoke solutions to customers, via a
growing on-line catalogue of Affimer reagents and, in the longer
term, by developing Affimers with therapeutic properties for
out-licensing.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMUAOKRVKABORR
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024
